Japanese encephalitis vaccine

Section: 19. Immunologicals > 19.3. Immunologicals > Vaccines

EMLc | Codes ATC: J07BA02 J07BA03

Indication	Need for immunization against certain single viral diseases Code ICD11: QC01
Type de médicament	Biological agent
Type de liste	Liste de base
Formulations	All vaccines should comply with the WHO requirements for biological substances.
Historique des statuts LME	Ajouté pour la première fois en 2007 (TRS 946) Modifié en 2007 (TRS 950) Modifié en 2019 (TRS 1021)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Balises	Biological
Wikipédia	Japanese encephalitis vaccine

Résumé des preuves et recommandation du comité d'experts

WHO immunization policy recommendations are published in vaccine position papers on the basis of recommendations made by the Strategic Advisory Group of Experts on Immunization (SAGE). WHO vaccine position papers are updated three to four times per year. Vaccines listed on the 2019 Model List are those for which there is a recommendation from SAGE and a corresponding WHO position paper as at December 2018. The February 2015 version of the WHO position paper for Japanese encephalitis vaccine is attached. The most recent versions of the WHO position papers, reflecting the current evidence related to a specific vaccine and the related recommendations, can be accessed at any time on the WHO website at: http://www.who.int/immunization/documents/positionpapers/en/index.html. Vaccine recommendations may be universal or conditional (e.g., in certain regions, in some high-risk populations or as part of immunization programmes with certain characteristics). Details are available in the relevant position papers, and in the Summary Tables of WHO Routine Immunization Recommendations available on the WHO website at: http://www.who.int/immunization/policy/immunization_tables/en/index.html. Selection of vaccines from the Model List will need to be determined by each country after consideration of international recommendations, epidemiology and national priorities.